Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Phase 1

• Conditions: Non-small Cell Lung Cancer
• Interventions: Other: standard lung cancer treament; Biological: CIK cells with PD-1 blocking; Biological: CIK cells without PD-1 blocking

• Registration Number: NCT03282435
• Lead Sponsor: Dalian University

Brief Summary

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-09
• Study First Submitted: 2017-09-12
• Study First Submitted QC: 2017-09-12
• Last Update Submitted: 2017-09-12
• Study First Posted: 2017-09-14
• Last Update Posted: 2017-09-14
• Study Start: 2018-01
• Primary Completion: 2023-01
• Study Completion: 2023-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• non-small cell lung cancer;
• more than 50% tumor tissues positive with PD-L1;
• EGFR and ALK wild type
• no other tumors

Exclusion Criteria

• with systematic diseases shortening survival

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
CIK cells without PD-1 blocking	standard lung cancer treament	CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
CIK cells with PD-1 blocking	CIK cells with PD-1 blocking	CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
CIK cells with PD-1 blocking	standard lung cancer treament	CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
CIK cells without PD-1 blocking	CIK cells without PD-1 blocking	CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive

Primary Outcome Measures

Name	Time	Method
progression-free survival	5 years
metastasis-free survival	5 years